Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 7.5%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was the recipient of a significant increase in short interest in January. As of January 31st, there was short interest totalling 18,600 shares, an increase of 7.5% from the January 15th total of 17,300 shares. Based on an average daily trading volume, of 11,200 shares, the days-to-cover ratio is currently 1.7 days. Currently, 0.2% of the shares of the stock are sold short.

Armata Pharmaceuticals Price Performance

Armata Pharmaceuticals stock traded up $0.10 during mid-day trading on Friday, hitting $2.11. 21,410 shares of the company traded hands, compared to its average volume of 10,023. Armata Pharmaceuticals has a one year low of $1.80 and a one year high of $4.48. The firm has a market cap of $76.16 million, a PE ratio of -1.28 and a beta of 0.87.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and set a $7.00 price target on shares of Armata Pharmaceuticals in a research report on Thursday, December 19th.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.